Document is current
Any future updates will be listed below
-
Authors
Oyama, Toshinao https://orcid.org/0009-0007-2235-1409
Brashears, Caitlyn B. https://orcid.org/0000-0001-6007-6056
Rathore, Richa https://orcid.org/0000-0003-3708-8758
Benect-Hamilton, Heather https://orcid.org/0009-0005-0385-4874
Caldwell, Katharine E.
Dirckx, Naomi
Hawkins, William G.
Van Tine, Brian A. https://orcid.org/0000-0003-4572-6668
- License Information
-
More Information
Article History
Received: 29 July 2024
Revised: 23 December 2024
Accepted: 21 January 2025
First Online: 12 February 2025
Competing interests
: BAVT declares grants from Merck; grants and personal fees from Pfizer; grants from TRACON Pharmaceuticals; grants, personal fees, and other remunerations from GlaxoSmithKline; personal fees from Polaris Inc.; personal fees from Lilly; personal fees from Caris Life Sciences; personal fees from Novartis; personal fees from CytRX; personal fees from Plexxikon; personal fees from Epizyme; personal fees from Daiichi Sankyo; personal fees from Adaptimmune; personal fees from Immune Design; personal fees from Bayer; personal fees from Cytokinetics; and personal fees from Deciphera; he has a patent issued for the use of ME1 as a biomarker and ACXT3102. WGH, SV and DS have intellectual property rights related to this work (US patents 8.168.650, 8.143.222, 7.612.085 and other patents pending). RR reports current employment by Verastem Oncology. TO, CB, KC, HBH Report no COI.
: Ethics approval for animal work was provided by Washington University in St. Louis Institutional Animal Care and Use Committee (protocol ID: 22-0350).
